Latest News and Press Releases

Presented Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones Priced Offering of $5 Million Convertible Redeemable Preferred Stock through a Private...

MONMOUTH JUNCTION, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy...

MONMOUTH JUNCTION, N.J., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy...

Updated data show a second partial response in Part B Overall response rate of 15.4% and disease control rate of 46% in Part B with durable clinical benefit in patients with prior disease...

MONMOUTH JUNCTION, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy...

Stockholders approved Proposal 1 in support of Biosight merger Proposal 2 reverse stock split, a condition for completing the merger of Advaxis and Biosight, was not approved MONMOUTH...

Stockholders passed Proposals 1 (the Merger) and 4 (Executive Compensation) Advaxis urges stockholders to vote “FOR” Proposal 2 at the upcoming special meeting in order to best position the...

Company releases video message highlighting the need for all proposals to pass in order to consummate the proposed Biosight transaction Advaxis urges stockholders to vote “FOR” all of the proposals...

MONMOUTH JUNCTION, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (“Advaxis” or the “Company”), a clinical-stage biotechnology company focused on the development and...

MONMOUTH JUNCTION, N.J., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy...